Patents by Inventor Jiansheng Yao
Jiansheng Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11114834Abstract: A complete set of tension backup device for carbon fiber wire, consisting of a backup tension device, a performed armor rod, a parallel hanging plate, an adapter base, a wire drawing device, a support damper clamp, a U-shaped pulling ring, a triangular hanging plate, and a tensioning device. The backup tension device is a backup strain clamp in a wedge-shaped structure. The support damper clamps are provided on carbon fiber split wires between an original strain clamp and the backup tension device, and arranged at intervals of 3-4 meters.Type: GrantFiled: October 10, 2018Date of Patent: September 7, 2021Inventors: JianSheng Yao, Xiaoqiang Zhu, DongYu Yao, XiaoLong Shi, YaYong Si, ShuPeng Tian, MengMeng Gao, YiXiang Zhou
-
Publication number: 20200350752Abstract: A complete set of tension backup device for carbon fiber wire, consisting of a backup tension device, a performed armor rod, a parallel hanging plate, an adapter base, a wire drawing device, a support damper clamp, a U-shaped pulling ring, a triangular hanging plate, and a tensioning device. The backup tension device is a backup strain clamp in a wedge-shaped structure. The support damper clamps are provided on carbon fiber split wires between an original strain clamp and the backup tension device, and arranged at intervals of 3-4 meters.Type: ApplicationFiled: October 10, 2018Publication date: November 5, 2020Inventors: JianSheng YAO, Xiaoqiang ZHU, DongYu YAO, XiaoLong SHI, YaYong SI, ShuPeng TIAN, MengMeng Gao, YiXiang ZHOU
-
Publication number: 20150265695Abstract: The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.Type: ApplicationFiled: July 24, 2013Publication date: September 24, 2015Inventors: Jiansheng Yao, Yves Girerd-Chambaz, Isabelle Legastelois, Nathalie Mantel, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20140120133Abstract: The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.Type: ApplicationFiled: October 22, 2013Publication date: May 1, 2014Applicants: MERIAL LIMITED, UNIVERSITY OF PRETORIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jules Maarten Minke, Jean Christophe Audonnet, Alan John Guthrie, Nigel James Maclachlan, Jiansheng Yao
-
Publication number: 20120114691Abstract: The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.Type: ApplicationFiled: January 25, 2012Publication date: May 10, 2012Inventors: Jules Maarten Minke, Jean-Christophe Audonnet, Alan John Guthrie, Nigel James Maclachlan, Jiansheng Yao
-
Patent number: 8168200Abstract: The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.Type: GrantFiled: October 22, 2009Date of Patent: May 1, 2012Assignees: Merial Limited, The Regents of the University of California, University of PretoriaInventors: Jules Maarten Minke, Jean-Christophe Audonnet, Alan John Guthrie, Nigel James MacLachlan, Jiansheng Yao
-
Patent number: 8008268Abstract: The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against vesicular stomatitis virus (VSV) in an animal susceptible to VSV. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain at least one heterologous nucleic acid molecule(s), expresses in vivo in the animal VSV antigen(s), immunogen(s) or epitope(s) thereof, e.g., VSV G protein and/or VSV N protein and/or VSV M protein. The heterologous nucleic acid molecule(s) may be adjusted to the vector/mammalian cell system by codon optimization. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.Type: GrantFiled: August 16, 2006Date of Patent: August 30, 2011Assignee: Merial LimitedInventors: Jiansheng Yao, Jules Maarten Minke, Jean Christophe Audonnet
-
Patent number: 7998733Abstract: The present invention relates to chimeric vectors. More specifically, the invention relates to recombinant poxvirus vectors and viruses that are capable of expressing an alphaviral RNA replicon expressing a heterologous sequence of interest.Type: GrantFiled: October 5, 2004Date of Patent: August 16, 2011Assignee: Merial LimitedInventors: Jiansheng Yao, Sheena May Loosmore, Jean-Christophe Francis Audonnet
-
Patent number: 7910112Abstract: The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against avian influenza.Type: GrantFiled: November 6, 2006Date of Patent: March 22, 2011Assignee: Merial LimitedInventors: Hervé Poulet, Jean Christophe Audonnet, Michel Bublot, Jiansheng Yao
-
Patent number: 7862821Abstract: The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against Orbiviruses, more specifically bluetongue virus (BTV) in an animal susceptible to BTV infection. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain heterologous nucleic acid molecule(s), expresses in vivo in the animal BTV antigen, immunogen or epitope thereof, e.g., BTV VP2; BTV VP2 and VP5; BTV VP2 and VP5 and VP3 and/or VP7. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.Type: GrantFiled: June 1, 2006Date of Patent: January 4, 2011Assignees: Merial Limited, The Regents of the University of CaliforniaInventors: Jean Christophe Francis Audonnet, Kemal Karaca, Jiansheng Yao, Nigel James MacLachlan
-
Publication number: 20100119546Abstract: The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.Type: ApplicationFiled: October 22, 2009Publication date: May 13, 2010Inventors: Jules Maarten Minke, Jean-Christophe Audonnet, Alan John Guthrie, Nigel James Maclachlan, Jiansheng Yao
-
Publication number: 20080241184Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: ApplicationFiled: January 28, 2008Publication date: October 2, 2008Inventors: Jules Maarten Minke, Kemal Karaca, Jiansheng Yao
-
Patent number: 7425336Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: GrantFiled: November 1, 2005Date of Patent: September 16, 2008Assignee: Mevial LimitedInventors: Jules Maarten Minke, Kemal Karaca, Jiansheng Yao
-
Patent number: 7384642Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: GrantFiled: August 25, 2005Date of Patent: June 10, 2008Assignee: Merial LimitedInventors: Jules Maarten Minke, Kemal Karaca, Jiansheng Yao
-
Publication number: 20080124357Abstract: The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against vesicular stomatitis virus (VSV) in an animal susceptible to VSV. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain at least one heterologous nucleic acid molecule(s), expresses in vivo in the animal VSV antigen(s), immunogen(s) or epitope(s) thereof, e.g., VSV G protein and/or VSV N protein and/or VSV M protein. The heterologous nucleic acid molecule(s) may be adjusted to the vector/mammalian cell system by codon optimization. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.Type: ApplicationFiled: August 16, 2006Publication date: May 29, 2008Inventors: Jiansheng Yao, Jules Maarten Minke, Jean Christophe Audonnet
-
Publication number: 20070280960Abstract: The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against Orbiviruses, more specifically bluetongue virus (BTV) in an animal susceptible to BTV infection. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain heterologous nucleic acid molecule(s), expresses in vivo in the animal BTV antigen, immunogen or epitope thereof, e.g., BTV VP2; BTV VP2 and VP5; BTV VP2 and VP5 and VP3 and/or VP7. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.Type: ApplicationFiled: June 1, 2006Publication date: December 6, 2007Inventors: Jean Christophe Francis Audonnet, Kemal Karaca, Jiansheng Yao, Nigel James MacLachlan
-
Publication number: 20070048819Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: ApplicationFiled: August 25, 2005Publication date: March 1, 2007Inventors: Jules Minke, Kemal Karaca, Jiansheng Yao
-
Publication number: 20070048821Abstract: The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.Type: ApplicationFiled: November 1, 2005Publication date: March 1, 2007Inventors: Jules Minke, Kemal Karaca, Jiansheng Yao
-
Publication number: 20060073594Abstract: The present invention relates to chimeric vectors. More specifically, the invention relates to recombinant poxvirus vectors and viruses that are capable of expressing an alphaviral RNA replicon expressing a heterologous sequence of interest.Type: ApplicationFiled: October 5, 2004Publication date: April 6, 2006Inventors: Jiansheng Yao, Sheena Loosmore, Jean-Christophe Audonnet